New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Re-classification rates on repeat biopsy for men on active surveillance in the Hopkins cohort

So there is an interesting new paper on the ramifications of active surveillance in the forthcoming June issue of the Journal of Urology — based on the extensive data now collected by the Johns Hopkins group through their very conservative active surveillance cohort of > 1,200 men accumulated since 1995. … READ MORE …

SpaceOAR hydrogel decreases rectal radiation dose, but is it worthwhile?

Earlier this month, the US Food and Drug Administration (FDA) cleared Augmenix Corporation’s hydrogel spacer for use in the US, as announced in their press release. The rectal spacer has been used in Europe since 2010. … READ MORE …

Intermittent vs. continuous ADT: the results of the ICELAND trial

The results of early, large, randomized trials of intermittent (IADT) vs. continuous androgen deprivation therapy (CADT) have provided conflicting results. However, one of the flaws in early trials was the failure to ensure that men enrolled into these trials all actually had an optimal initial response to androgen deprivation (ADT). … READ MORE …

The EMBARK trial in men with progressive but non-metastatic prostate cancer

We apparently managed to miss providing readers with information about initiation of what may be a game-changing, randomized, Phase III, trial in the treatment of progressive prostate cancer. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,285 other followers